1 study found for:    ADVL0921
Show Display Options
Rank Status Study
1 Active, not recruiting Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Hepatoblastoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Kidney Neoplasm;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study

Indicates status has not been verified in more than two years